Skip to main content
Article thumbnail
Location of Repository

Decreased risk of breast cancer associated with oral bisphosphonate therapy

By A Mathew and A Brufsky


Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their use has been fraught with significant adverse effects such as venous thromboembolic events and an increased risk for endometrial cancer. In this context, several recent observational studies have investigated a chemoprevention role for oral bisphosphonates in decreasing risk for breast cancer. This review will aim to summarize these studies and present a critical evaluation of the association between oral bisphosphonate use and breast cancer risk reduction. © 2012 Mathew and Brufsky, publisher and licensee Dove Medical Press Ltd

Year: 2012
OAI identifier:
Provided by: D-Scholarship@Pitt

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.